Compounds for targeted degradation of BRD9

1. A method of treating a disorder mediated by BRD9 comprising administering an effective amount of a compound of Formula:

or a pharmaceutically acceptable salt thereof to a human in need thereof;

wherein:

Q 1 is selected from the group consisting of NH, N(alkyl), N(haloalkyl), CH 2 , a, and S;

X 3 is N, CH, or CR 3 ;

X 10 is Cc(R 7 ) 2 , C(O), or O;

X 11 is a heterocycle optionally substituted with 1, 2, or 3 groups independently selected from R 3 ;

X 16 is selected from the group consisting of N, CH, and CR 4 ;

R 3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, alkoxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, cycloalkyl, fluorine, chlorine, bromine, and iodine;

each R 4 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkyl, fluorine, chlorine, bromine, and iodine;

each R 7 is independently hydrogen, methyl, or ethyl; and

R 8 is hydrogen, C 1 -C 4 alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl.

2. The method of claim 1 , wherein the compound is of Formula:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein Q 1 is NH.

4. The method of claim 3 , wherein X 10 is CH 2 .

5. The method of claim 4 , wherein each R 7 is CH 3 .

6. The method of claim 5 , wherein X 11 is selected from:

7. The method of claim 6 , wherein the BRD9 mediated disorder is synovial sarcoma.

8. The method of claim 6 , wherein the BRD9 mediated disorder is a SMARCB1-perturbed cancer.

9. The method of claim 1 , wherein the compound is of structure

or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the BRD9 mediated disorder is synovial sarcoma.

11. The method of claim 9 , wherein the BRD9 mediated disorder is a SMARCB1-perturbed cancer.